FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				01	Jeene	311 30(11) (or tire	invesiment C	ompany Act	01 1340							
1. Name and Address of Reporting Person* <u>Luly Jay R.</u>					2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC ENTA							Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle)					ENIA 1							X Officer (give title below)			Other (s below)	pecify	
C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET					3. Date of Earliest Transaction (Month/Day/Year) 01/10/2014							President and CEO					
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
WATER	TOWN MA 02472											X Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)			(Zip)									Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transaction te onth/Day/Ye	Execution Date,			Code (Instr. 5)			ed (A) or str. 3, 4 and	Benefici	es ally Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) o (D)	r Price	Transac (Instr. 3	ction(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$14	01/10/2014		A		6,957		01/10/2014	03/20/2023	Common Stock	6,957	\$0	6,957 ⁽¹ .)	D		

Explanation of Responses:

1. On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which does not become reportable on Form 4 until the option becomes exercisable. The option becomes exercisable in up to nine installments, six of which are installments of 8.33% of the shares and three of which are installments of 16.67% of the shares, based on ENTA's achievement of certain clinical milestones with respect to three or more programs that progress to clinical development. The clinical milestone for one 8.33% installment was achieved on January 10, 2014, resulting in the vesting of the option as to 6,957 shares.

Remarks:

/s/ Nathaniel S. Gardiner as attorney-in-fact

05/02/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.